5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | SELL | NEUTRAL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 238.88▲ | 238.78▲ | 238.72▲ | 233.29▲ | 246.32▼ |
MA10 | 238.59▲ | 238.85▲ | 239.41▼ | 235.26▲ | 254.22▼ |
MA20 | 238.47▲ | 239.62▼ | 237.09▲ | 247.30▼ | 239.93▼ |
MA50 | 238.55▲ | 234.55▲ | 233.03▲ | 253.14▼ | 215.42▲ |
MA100 | 239.55▼ | 233.35▲ | 241.14▼ | 235.93▲ | 216.59▲ |
MA200 | 237.52▲ | 242.48▼ | 253.14▼ | 216.29▲ | 261.38▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.131▲ | -0.471▼ | -0.058▼ | -1.190▼ | -2.015▼ |
RSI | 59.765▲ | 55.855▲ | 58.832▲ | 43.308▼ | 52.506▲ |
STOCH | 78.617 | 36.575 | 19.958▼ | 30.763 | 55.459 |
WILL %R | -22.634▲ | -70.230 | -70.230 | -54.548 | -55.779 |
CCI | 211.680▲ | -7.245 | -42.170 | -3.740 | -37.902 |
Tuesday, April 23, 2024 02:36 PM
Johnson Fistel, LLP ( a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River ...
|
Tuesday, April 23, 2024 02:09 PM
Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab According to the complaint, during the class period, ...
|
Tuesday, April 23, 2024 11:06 AM
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the company’s Biologics License Application (BLA) for pz-cel for the treatment of patients with ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
24/04/24 | 239.28 | 244.56 | 237.44 | 239.43 | 705,117 |
23/04/24 | 237.83 | 242.91 | 236.22 | 240.13 | 611,881 |
22/04/24 | 228.95 | 232.665 | 225.79 | 232.56 | 544,691 |
19/04/24 | 227.14 | 230.34 | 225.6468 | 226.78 | 409,097 |
18/04/24 | 228.02 | 233.72 | 223.49 | 227.55 | 710,218 |
17/04/24 | 234.40 | 234.40 | 229.85 | 230.09 | 499,836 |
16/04/24 | 235.92 | 235.92 | 231.395 | 232.34 | 336,008 |
15/04/24 | 244.32 | 244.41 | 234.17 | 235.93 | 462,301 |
12/04/24 | 244.07 | 246.567 | 239.66 | 241.34 | 389,716 |
11/04/24 | 249.30 | 250.72 | 246.24 | 246.42 | 320,904 |
|
|
||||
|
|
||||
|
|